However, recent studies have revealed that YAP can function as a context-dependent tumor suppressor in several types of cancer including hematological cancers (21), estrogen receptor α (ERα) positive breast cancer (22, 23), androgen receptor (AR) positive prostate cancer (24), and VHL negative clear cell renal cell carcinoma (ccRCC) (25). Here, YAP1 is linked to nonpapillary renal cell carcinoma.